A venture capital firm with ties to a family office invests mainly in Seed to Series A/B, with an initial check ranging between 3-7 million Euros. Follow-on investments are possible, and the firm may invest up to 15 million Euros throughout the life cycle. The firm is open to both leading and co-investing. The firm focuses on opportunities in Europe, UK and US.
The firm is interested in early-stage therapeutic technologies. The firm is agnostic regarding modalities and indications, and is open to exploring different types of therapeutic assets. Additionally, the firm has invested in orphan drugs. While there is no strict mandate for the development phases of assets, having at least in-vivo data would generally be preferred.
There are no specific requirements for companies’ management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.





Leave a comment